What science
金沙国际


Annual Report & Form 20-F
金沙国际

01

金沙国际

This Annual Report quick-阅读 provides top-level 资讯rmation on our business and the progress we have made in 2017 in pushing the boundaries of science to deliver life-changing medicines.


Watch the video on 'what science can do'金沙国际

02

金沙国际



One of the Board’s basic responsibilities is to set our strategy and monitor progress towards meeting our objectives, so that we bring our science to patients, create value for society, and reward you, our shareholders.

Leif Johansson Chairman

2017 represented a defining year for AstraZeneca. 2018 will be equally important as we seek to deliver the full potential of our medicines and ensure we deliver our science to patients around the world.

Pascal Soriot CEO

03

金沙国际


In 2017, our financial performance reflected the launch of several new medicines, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR金沙国际


金沙国际

Total Revenue

金沙国际

 

Net cash flow from operating activities

金沙国际

 

Reported operating profit

金沙国际

 

Core operating profit

金沙国际

 

Reported EPS

金沙国际

 

Core EPS

金沙国际

 

04

金沙国际

We are a global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

金沙国际

金沙国际

2016: $21,319m
2015: $23,641m
金沙国际



金沙国际


金沙国际



金沙国际

金沙国际

金沙国际

金沙国际

金沙国际

金沙国际




金沙国际

金沙国际


金沙国际

金沙国际

Pence: 68.9
SEK: 7.40
金沙国际

金沙国际

金沙国际

Pence: 133.6
SEK: 14.97
金沙国际

金沙国际

金沙国际

Pence: 202.5
SEK: 22.37

金沙国际


05

金沙国际

We announced our strategy for returning to growth in 2013. We moved on from the first phase in our journey, focused on rebuilding our pipeline, in 2015. The second stage is crucial as we drive our Growth Platforms forward, continue to launch new medicines and make them available to patients. As we look ahead to 2020 and beyond, continued investment in our pipeline will keep us on track to return to sustainable growth in line with our targets.

In 2017, our strategic priorities were focused under the three pillars described below.

  • 金沙国际

    We are focusing our science on three therapy areas and accelerating our pipeline. We are also transforming our way of working.


  • 金沙国际

    We are focusing on our Growth Platforms and transforming the business through specialty care, devices and biologic medicines. Targeted business development re资讯rces our efforts.


  • 金沙国际

    We are evolving our culture and simplifying our business. We want to attract and retain the best talent. We also want to do business sustainably.



金沙国际

金沙国际